

Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: November 28, 2022

Time: 1:00-3:00PM

Microsoft Teams meeting

| Time | Topic | Description | Presenter(s) |
|----------------------|--|--------------------------------------|---|
| 1:00-1:15 | <ul style="list-style-type: none"> Welcome Agenda and Objectives Conflict of Interest (COI) Declarations | Inform members | Interim Chair |
| 1:15-2:15 | <ul style="list-style-type: none"> Trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive serous endometrial cancer | Submission [voting item] | Lead Presenter Clinical Presenter Pharmacoeconomic (PE) Presenter |
| ***5-minute break*** | | | |
| 2:20-2:50 | <ul style="list-style-type: none"> Raltitrexed for dihydropyrimidine dehydrogenase (DPD) deficiency in gastrointestinal cancers | Request for Advice [non-voting item] | Clinical Presenter Budget Impact Analysis (BIA) Presenter Alternate committee member will be acting Interim Chair for this item |
| 2:50-3:00 | <ul style="list-style-type: none"> Closing remarks <ul style="list-style-type: none"> Housekeeping Items 2023 Meeting Series | Inform members | Interim Chair |